AACR Annual Meeting 2023 AACR 2023: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC
Gastrointestinal Cancers ASCO GI 2024: ctDNA as a Predictive Biomarker for Patients With Colon Cancer